Working… Menu

An Open-Label Study to Evaluate the Response to Adalimumab in Patients With Active Ankylosing Spondylitis Who Have Failed Standard Therapy or TNF-Alpha Inhibitors (RHAPSODY) (RHAPSODY)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00478660
Recruitment Status : Completed
First Posted : May 25, 2007
Last Update Posted : October 10, 2007
Information provided by:

Brief Summary:

Due to the rigor of the clinical development program of adalimumab for the indication of AS, the population of subjects with active AS that could enroll in previous phase 3 studies was limited. Therefore, it is necessary to further evaluate the use of adalimumab in a setting that mimics day-to-day clinical practice to obtain further safety and efficacy data by allowing subjects meeting the characteristics noted below to enter this study:

  • Subjects who failed another TNF inhibitor (etanercept, infliximab)
  • Subjects with advanced spinal ankylosis
  • Subjects with AS associated disorders (i.e., uveitis, IBD, and psoriasis)

Condition or disease Intervention/treatment Phase
Ankylosing Spondylitis Drug: adalimumab (Humira) Phase 3

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 1250 participants
Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: Double
Primary Purpose: Treatment
Official Title: Review of Safety and Efficacy With Adalimumab in Patients With Active Ankylosing Spondylitis - An Open-Label Study to Evaluate the Response to Adalimumab in Patients Who Have Failed Standard Therapy or TNF-Alpha Inhibitors (RHAPSODY)
Study Start Date : February 2006

Resource links provided by the National Library of Medicine

Drug Information available for: Adalimumab

Primary Outcome Measures :
  1. ASAS 20/40/50/70
  2. ASAS 5/6
  3. BASDAI score

Secondary Outcome Measures :
  1. Adverse events
  2. Laboratory data
  3. Vital signs

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Able and willing to give written informed consent and to comply with the requirements of the study protocol
  • Males and females 18 years of age or older
  • Diagnosis of AS according to the modified New York Criteria for Ankylosing Spondylitis 1984.24
  • Documented active AS based on the opinion of a physician for at least 3 months
  • Active AS with BASDAI >= 4 at the Screening Visit
  • Unsatisfactory response to standard AS therapies in accordance with the current national guidelines for treatment of AS with TNF inhibitors (if applicable) including a minimum of failing at least one NSAID. National guidelines (if applicable) must be followed if the guidelines are more strict regarding the use of TNF inhibitors for the treatment of AS
  • Use of reliable method of contraception, e.g., IUDs, condoms, or hormone (oral, implantable, or injectable) contraceptives by all female subjects of childbearing potential. Subject must follow the manufacture's recommendations of contraception prior to the administration of study drug and through 150 days following the last administration of adalimumab
  • Able and willing to self-administer sc injections or have available a suitable person to administer sc injections
  • A negative pregnancy test (serum HCG) for women of childbearing potential prior to start of study treatment
  • Subject must be evaluated for active and latent TB infection by using a PPD skin test, T SPOT-TB test, chest x-ray and a detailed review of the subject's medical history. Guidelines regarding the treatment of latent TB must be followed prior to the administration of adalimumab

Exclusion Criteria:

  • Prior treatment with any investigational agent within 30 days, or five half-lives of the product, which ever is longer
  • Treatment within the last six weeks with infliximab or within the last three weeks with etanercept or previous treatment at any time with adalimumab
  • Known allergy to excipients of adalimumab formulation
  • History of or current acute inflammatory joint disease of origin other than AS, e.g., rheumatoid arthritis, psoriatic arthritis, systemic lupus erythematosus etc
  • Treatment with corticosteroids (prednisolone equivalents) under the following conditions:

    • Dose is >10 mg/d systemically within the 28 days before screening
    • Intraarticular injections or infiltrations of peripheral joints and tendons within 28 days before or at screening
    • Intraarticular injections of sacroiliac joints without therapeutic response <=14 days before screening
  • Other medical conditions: uncontrolled diabetes, unstable ischemic heart disease, congestive heart failure (NYHA III-IV), recent stroke (within three months), chronic leg ulcer and any other condition (e.g., indwelling urinary catheter) which, in the opinion of the investigator, would put the subject at risk by participation in the study
  • History of cancer or malignant lymphoproliferative disease other than a successfully treated non-metastatic cutaneous squamous cell or basal cell carcinoma and/or localized carcinoma in situ of the cervix
  • History of positive serology for hepatitis B indicating active infection or history of positive serology for hepatitis C
  • History of positive HIV status
  • Persistent or recurrent infections or severe infections requiring hospitalization or treatment with iv antibiotics within 30 days, or oral antibiotics within 14 days prior to enrollment
  • Previous diagnosis or signs highly indicative of central nervous system demyelinating diseases (e.g., optic neuritis, ataxia, apraxia)
  • History of active tuberculosis, histoplasmosis or listeriosis
  • Female subjects who are pregnant or breast-feeding
  • History of clinically significant drug or alcohol abuse in the last year

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00478660

Show Show 205 study locations
Sponsors and Collaborators
Layout table for investigator information
Study Director: Beverly Paperiello Abbott
Publications automatically indexed to this study by Identifier (NCT Number):
Layout table for additonal information Identifier: NCT00478660    
Other Study ID Numbers: M05-760
First Posted: May 25, 2007    Key Record Dates
Last Update Posted: October 10, 2007
Last Verified: October 2007
Additional relevant MeSH terms:
Layout table for MeSH terms
Spondylitis, Ankylosing
Bone Diseases, Infectious
Bone Diseases
Musculoskeletal Diseases
Spinal Diseases
Joint Diseases
Anti-Inflammatory Agents
Antirheumatic Agents